 BARCELONA, Spain, July 4, 2019 PRNewswire -- Grifols GRF.MC GRF.P.MC GRFS, a leading global producer of plasma-derived medicines, announced today that Xembify, its new 20 subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration FDA. Xembify is used to treat primary immunodeficiencies. 